ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announced a conference call on May 9, 2022, at 8:30 a.m. ET to discuss its first-quarter financial results and business updates. The call will be accessible via phone and live webcast, with an archived version available for 30 days. The company specializes in targeted antibody drug conjugates for cancer treatment, with its FDA-approved ADC ZYNLONTA (loncastuximab tesirine-lpyl) for diffuse large B-cell lymphoma. ADC Therapeutics is advancing additional clinical trials, including Cami for Hodgkin lymphoma and various solid tumors.

Positive

• ADC Therapeutics will report Q1 2022 financial results, providing insights into current business performance.
• The company's ADC ZYNLONTA is FDA-approved, indicating regulatory validation and potential revenue generation.
• Ongoing clinical trials for Cami could expand ADC Therapeutics' product pipeline and market potential.

Negative

• None.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Monday, May 9, 2022 at 8:30 a.m. ET to report financial results for the first quarter 2022 and provide business updates.

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference ID 6928367. A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA^® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005540/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

Tel.: +44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

Tel.: +1 917 288 7023

EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

Tel: +41 (0) 43 268 3231

USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

Tel.: +1 914-552-4625

Source: ADC Therapeutics SA

FAQ

What is ADC Therapeutics planning to announce on May 9, 2022?

ADC Therapeutics will discuss its first-quarter financial results and provide business updates.

What is ZYNLONTA and its significance for ADC Therapeutics?

ZYNLONTA is an FDA-approved ADC for treating relapsed or refractory diffuse large B-cell lymphoma, which contributes to ADC Therapeutics' revenue potential.

Where can I find the webcast for ADC Therapeutics' conference call?

The live webcast will be available in the 'Events and Presentations' section of ADC Therapeutics' investor website.

What ongoing trials is ADC Therapeutics conducting?

ADC Therapeutics is evaluating Cami in pivotal trials for Hodgkin lymphoma and advanced solid tumors.

What does ADC Therapeutics specialize in?

ADC Therapeutics specializes in next-generation, targeted antibody drug conjugates for cancer treatment.